Challenges in the Development and Commercialization of Liquid Biopsy Products

Triveni Triveni
Published on Apr 18, 2023

The global Liquid Biopsy Market was USD 1746.9 Million in 2022 and is predicted to grow at a CAGR of 20.7% during the forecast period. Factors like the increasing prevalence of cancer, new clinical trials and initiatives, and rising investments, along with increasing healthcare expenditure, are driving the revenue growth of the liquid biopsy market globally. The non-invasive nature of liquid biopsy, along with its simplicity and speed in collecting samples, possibility of early detection, and ability to track disease progression and treatment effectiveness in real-time are some of its primary benefits. The advancement of nanotechnology has significantly improved various liquid biopsy applications. Employing nanomaterials for biosensing has advantages such as high sensitivity and detectability, affordability, portability, quick analysis, and the potential for personalized treatment. These factors contribute to the revenue growth of the global liquid biopsy market, along with companies receiving investments and funding.

For example, US-based liquid biopsy test provider, Delfi Diagnostics, received USD 225 million in a Series B investment round led by venture capital company DFJ Growth on 20 July 2022. New investors in the round include Eli Lilly & Company, Brown Advisory, Initiate Ventures, Point72, Open Field Capital, PTX Capital, and Point Field Partners. Delfi aims to use the funding to develop and promote its superior blood tests for the early detection of single and multiple tumors and treatment monitoring. The company is currently verifying the technique for early identification of lung and other malignancies with the enrollment of 15,000 people. Furthermore, the increasing preference for non-invasive or minimally invasive treatment methods is also driving the revenue growth of the liquid biopsy market. Minimally invasive therapeutic treatments are preferred by patients as it entails no or fewer incisions, causes less discomfort, leaves no unsightly scars, and requires fewer hospital stays, thereby reducing costs. Additionally, it shortens the healing process and lowers the possibility of side effects such as intestinal adhesions, incisional hernias, and wound dehiscence, making it a preferred choice among surgeons as well. These declarations by notable healthcare authorities are resulting in more individuals opting for such procedures, which is expected to drive the revenue growth of the liquid biopsy market during the forecast period.

Request a sample Report of Liquid Biopsy Market @

Major companies in Liquid Biopsy Market:

  • Qiagen
  • Guardant Health
  • Bio-Rad Laboratories, Inc.
  • NeoGenomics Laboratories
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Biocept, Inc.
  • Hoffmann-La Roche Ltd.
  • Adaptive Biotechnologies

Request latest Report Insights of  Liquid Biopsy Market @

Driving Factors in Liquid Biopsy Market:

  1. Increasing prevalence of cancer
  2. Non-invasive nature of liquid biopsy
  3. Ability to track the progression of disease and effectiveness of treatment in real-time
  4. Rising investments and funding
  5. Increasing healthcare expenditure
  6. Minimally invasive treatment methods
  7. Possibility of early discovery of cancer
  8. Advancements in nanotechnology
  9. Potential for individualized treatment
  10. High sensitivity and detectability of nanomaterials

Restraints in Liquid Biopsy Market:

  1. Limited clinical validation of liquid biopsy tests compared to traditional tissue biopsy.
  2. The high cost of liquid biopsy tests compared to conventional biopsy techniques.
  3. Technical limitations associated with the sensitivity and specificity of liquid biopsy tests.
  4. Lack of standardization and regulatory guidelines for liquid biopsy testing.
  5. Limited awareness and adoption of liquid biopsy tests in certain regions or healthcare settings.
  6. Risk of false positives or negatives in liquid biopsy testing results.
  7. Ethical concerns regarding the use of liquid biopsy for certain types of genetic testing.
  8. Limited availability of liquid biopsy tests for certain types of cancer or genetic abnormalities.

Request a Report Customization of Liquid Biopsy Market @

Notable Innovations in Liquid Biopsy Market:

  1. Circulating tumor DNA (ctDNA) analysis
  2. Single-cell analysis
  3. Next-generation sequencing (NGS) technology
  4. Digital droplet PCR (ddPCR) technology
  5. Methylation-based liquid biopsy
  6. Protein-based liquid biopsy
  7. MicroRNA (miRNA) profiling
  8. Exosome-based liquid biopsy
  9. Cell-free RNA analysis
  10. Electrochemical biosensors

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Reports And Data | Web:
Direct Line: +1-212-710-1370
LinkedIn | Twitter | Blogs